William Blair Has Bearish Estimate for VRTX Q3 Earnings

Key Points

• William Blair has lowered its Q3 2025 earnings estimate for Vertex Pharmaceuticals to $4.11 per share, down from a previous estimate of $4.13.
• The consensus estimate for Vertex's full-year earnings in 2025 is projected at $15.99 per share.
• Despite the bearish forecast from William Blair, other analysts, like Citigroup, have increased their price target on Vertex shares and rated it as a "buy."

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) - Analysts at William Blair cut their Q3 2025 earnings per share estimates for Vertex Pharmaceuticals in a note issued to investors on Friday, October 10th. William Blair analyst M. Minter now anticipates that the pharmaceutical company will post earnings of $4.11 per share for the quarter, down from their previous estimate of $4.13. The consensus estimate for Vertex Pharmaceuticals' current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals' FY2025 earnings at $15.99 EPS.

VRTX has been the subject of several other reports. Raymond James Financial assumed coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a "market perform" rating for the company. Weiss Ratings restated a "hold (c+)" rating on shares of Vertex Pharmaceuticals in a research report on Wednesday, October 8th. Leerink Partners upgraded shares of Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and lowered their price objective for the company from $458.00 to $456.00 in a research report on Thursday, September 25th. Citigroup boosted their price objective on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the company a "buy" rating in a research report on Thursday, October 2nd. Finally, HC Wainwright lowered their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a "buy" rating for the company in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $494.38.

Vertex Pharmaceuticals Trading Down 1.7%

Shares of VRTX stock opened at $407.79 on Monday. The stock has a market cap of $104.55 billion, a P/E ratio of 29.15 and a beta of 0.43. The stock has a 50 day simple moving average of $393.91 and a 200 day simple moving average of $438.74. Vertex Pharmaceuticals has a 1 year low of $362.50 and a 1 year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The firm's revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS.

Insider Buying and Selling

In other news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director owned 45,000 shares of the company's stock, valued at $17,535,600. The trade was a 12.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.20% of the company's stock.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in VRTX. Activest Wealth Management bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd boosted its position in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after purchasing an additional 45 shares in the last quarter. Access Investment Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $27,000. Legacy Investment Solutions LLC bought a new position in shares of Vertex Pharmaceuticals during the 2nd quarter worth about $29,000. Finally, Flaharty Asset Management LLC bought a new position in shares of Vertex Pharmaceuticals during the 1st quarter worth about $32,000. Institutional investors own 90.96% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.